113 results about "AMI - Acute myocardial infarction" patented technology

An emergency system for treatment of a patient (20) experiencing an acute vascular obstruction, employing a non-invasive vibrator (10), optimally in conjunction with drugs, for disrupting and lysing thromboses, relieving spasm (if associated), and thereby restoring blood perfusion. Vibrator (10) is operable in the sonic to infrasonic range, with a source output of up to 15 mm. For acute myocardial infarction cases, a pair of contacts (12), are advantageously placed to bridge the sternum at the fourth intercostal space. Vibration is initiated at 50 Hz (or any frequency, preferably within the 20-120 Hz range), and is ideally adjusted to a maximal amplitude (or force) deemed tolerable and safe to the patient (20), preferably with the administration of thrombolytic agents or other form of drug therapy. A synergistic effect is achieved between vibration and drugs to facilitate the disruption of thromboses, relieve spasm, and restore blood perfusion. In a variation, ultrasonic imaging may be used to direct vibration therapy.

The invention relates to a preparing method of a photoelectrochemical sensor based on sandwich cardiac troponin T marked by Ag2Se@CdSe and application, and belongs to the technical field of novel functional materials and biosensing detection. According to concrete contents of the preparing method and the application, CeO2-TiO2 composite nanometer materials with photoelectrocatalytic activity are used as optical activity substrate materials; Ag2Se@CdSe is used as an antibody marker; the sandwich photoelectrochemical sensor is prepared through the signal amplification effect of the marker Ag2Se@CdSe on the substrate materials, and is used for the high-sensitivity detection of the cardiac troponin T of myocardial damage specific marker. The method has the important significance on the early diagnosis and treatment of acute myocardial infarction.

A method for differentiating acute myocardial infarction (AMI) from other ECG abnormalities. The method is performed by modeling selected ECG confounders that tend to obscure AMI evidence in the ECG waveform, and by purging a subject's ECG waveform of the effect(s) of these confounders through linking selected confounder models with an appropriate, computer-implementable purge algorithm.

The invention discloses an acute myocardial infarction diagnosis-oriented biosensor and a preparation method thereof. The sensor comprises a sensor matrix with a field effect tube (FET) structure, and a micro channel system layer, wherein the sensor matrix comprises a silicon-on-insulator (SOI) silicon chip; the surface of the silicon chip is provided with a passivation layer, silicon nanowires of which the surfaces are coupled with monoclonal antibody modified by acute myocardial infarction marker protein, and electrodes; at least local surfaces of the nanowires are exposed in a micro channel in the micro channel system layer; the micro channel is communicated with a sample solution inlet and a sample solution outlet on the micro channel system layer; and the sensor is prepared by a micro-nano processing method. The sensor can detect various marker proteins in serum by an electrical measurement means so as to acquire the degree of myocardial infarction attack. The biosensor can quickly and sensitively detect the myocardial infarction, has high response speed and diagnostic rate, and is suitable for the field of clinical medical detection.

The invention relates to an acute myocardial infarction marker and an application thereof, and in particular relates to RFX2 and an application of an agonist thereof in preparing a medicine for diagnosis and treatment on acute myocardial infarction. Based on a high-flux sequencing result, the inventor screens out the RFX2 gene; a molecular biology method verifies that RFX2 has low expression in the peripheral blood and the cardiac muscle tissue of the acute myocardial infarction. The invention provides the potential diagnosis and treatment target spot of the acute myocardial infarction, and has great clinical application values.

The invention relates to application of E1A-simulated gene cellular repressor (CREG) protein, in particular to application of CREG protein or active fragment thereof in preparation of drug used for preventing and / or treating acute myocardial infarction, heart failure after acute myocardial infarction and / or ventricular remodeling after the same. The invention further relates to application of recombinant vector or recombinant cell expressing the CREG protein or the active fragment thereof in preparation of the drug used for preventing and / or treating acute myocardial infarction, heart failure after acute myocardial infarction and / or ventricular remodeling after the same.

The invention belongs to the immunology field in medicine and particularly relates to a B-cell epitope peptide of H-FABP and applications of an antibody thereof. The epitope peptide is shown in SEQ ID NO.5 and can be used for preparing hybridoma cell lines and secreting a corresponding monoclonal antibody. The monoclonal antibody is capable of being used for preparing a diagnostic reagent which is used for detecting the H-FABP and prepared on a large scale, provided with purity higher than 96%, good in specificity and the like; and a detection titer of a purified antibody through an indirect enzyme-linked immunosorbent assay (ELISA) reaches 1:256,000. Monoclonal antibodies and polyclonal antibodies prepared through the epitope peptide can be used for H-FABP detection in patients' blood, and a foundation is laid for early diagnosis of acute myocardial infarction (AMI).

Provided is a method of distinguishing among Stanford type A acute aortic dissection, Stanford type B acute aortic dissection, and acute myocardial infarction, which are mutually similar in terms of clinical symptoms, and a kit for the distinguishment. Specifically, provided is a method of distinguishing among Stanford type A acute aortic dissection, Stanford type B acute aortic dissection, and acute myocardial infarction, which comprises detecting both D-dimer and H-FABP in blood separated from a person suspected of having acute aortic dissection and suspected of having acute myocardial infarction, and establishing the diagnosis on the basis of the concentrations detected, and a kit for the distinguishment.

The invention provides an application of miRNA, a product of using the same, and a detection method thereof, and relates to the technical field of medical molecular biology. The invention provides a miR-17-5p, miR-126-5p or miR-145-3p marker set taken as a marker for assisting the early diagnosis of heart diseases. The matured marker can stably exist in cytoplasm, thus, in acute myocardial infarction, miRNA in serum is released and enters a blood circulation system before structural proteins, and people can detect the level of the miRNA to assist the early diagnosis of acute myocardial infarction. Selected three markers are strongly complementary, and can all be taken as the markers for the early diagnosis of heart diseases. After three markers are used together, the precision is improved,and the sensitivity and specificity of disease diagnosis are greatly improved.

The invention relates to the technical field of genetic engineering, and discloses long-chain non-encoded RNA ENST00000581794.1 as well as a kit and an application thereof. The sequence of the long-chain non-encoded RNA ENST00000581794.1 is as shown in SEQ ID NO:1. A long-chain non-encoded expression profile chip technique is used, and a piece of lncRNA ENST00000581794.1 which is remarkably and highly expressed in blood of patients suffering from acute myocardial infarction can be screened through differential analysis, so that study on pathogenesis of acute myocardial infarction is further enriched.

The invention provides an application of an miRNA marker for diagnosing acute myocardial infarction, a product using the miRNA marker and a detection method, and relates to the technical field of medical molecular biology. The miR-26a-1, miR-146a or miR-199a-1 can be singly or jointly applied as markers for assisting early diagnosis of myocardial infarction, and the plasma level of the miR-26a-1,miR-146a or miR-199a-1 is obviously increased in the early stage of occurrence of myocardial infarction; and the miRNA in the blood of patients with acute myocardial infarction is released into the blood earlier than intracellular protein markers, so that the detection of the plasma level of the miRNA can be used as a biomarker for assisting early diagnosis of acute myocardial infarction. The three miRNA markers can be used as markers for early diagnosis of heart diseases, and thus the sensitivity and specificity of disease diagnosis are greatly improved.

A combination therapy for the treatment of acute myocardial infarction comprises administering a combination of a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof to a patient. The combination synergistically reduces mortality of patients with acute myocardial infarction.

The invention discloses a kit for jointly detecting acute myocardial infarction biomarkers. The kit comprises a working microsphere probe solution, a human cTn I series gradient standard substance solution, a human CK-MB series gradient standard substance solution, a human MYO series gradient standard substance solution, a triple acute myocardial infarction biomarker monoclonal antibody solution, a 100 * diluted streptavidin phycoerythrin solution and a 200 * diluted biotinylated mouse anti-human secondary antibody IgG solution. The kit establishes a high-throughput detection method of an AMI biomarker, can simultaneously and rapidly detect cTn I, CK-MB and MYO within 2 h, is suitable for the early diagnosis of AMI and finding of the AMI, improves the diagnosis rate of the AMI, and has high clinic examination application values in the early screening, disease condition monitoring, curative effect observation and recurrence judgment prediction and other stages of the AMI.

The invention discloses application of EMD638683 in protection of the heart suffering from acute myocardial infarction. The invention provides application of EMD638683 in preparation of products having the following functions: 1) prevention and / or treatment of myocardial infarction of animals; 2) prevention and / or treatment of heart failure caused by myocardial infarction of animals; and 3) inhibition of the expression of SGK1 protein in cardiac muscle tissue after myocardial infarction of animals. Experimental results of the invention prove that EMD638683 has treatment effect on mice with myocardial infarction, and experimental data is provided for clinical application of EMD638683 in treatment of myocardial infarction. The EMD638683 is of important theoretical significance to research on and development of medicines used for preventing and treating heart failure caused by myocardial infarction and has good application prospects.

The invention belongs to the field of Chinese medicinal science and particularly relates to a Chinese medicinal composition for adjunctively treating left ventricular insufficiency after acute myocardial infarction and a preparation method thereof. The Chinese medicinal composition is prepared from the following raw materials: ginseng, radix aconiti carmichaeli, szechuan lovage rhizome, radix salviae miltiorrhizae, sanchi, astragalus, sanguisuga and angelica. The Chinese medicinal composition has obvious improvement effect on the functions of the left heart of a patient after acute myocardial infarction, overcomes the drawbacks of western medicaments used alone, such as slow or no restoration of the functions of the left heat and lots of untoward effects, and is a new effective means for treating left ventricular insufficiency after acute myocardial infarction.

The invention relates to the technical field of biological engineering myocardial infarction related genes, and relates to a lncRNA NR-047662.2 and an in-vitro detection reagent, preparation or kit, applications and a detection method; the long non-coding RNA NR-047662.2 has a nucleic acid sequence as shown in SEQ ID No:1. The long non-coding RNA NR-047662.2 can provide new blood biomarkers and therapeutic targets for early diagnosis and prognosis monitoring of acute myocardial infarction, and further enriches the research on a pathogenesis of acute myocardial infarction.

The invention relates to a natriuretic peptide from a snake and a gene encoding the polypeptide. The natriuretic peptide disclosed by the invention is the natriuretic peptide from dendroaspis angusticeps. The natriuretic peptide disclosed by the invention is the brand new natriuretic peptide and a new member in a natriuretic peptide family, and is further called as GNP, namely G type natriuretic peptide. The invention further provides a preparation method of the recombinant natriuretic peptide. The natriuretic peptide provided by the invention comprises the recombinant natriuretic peptide and an artificially synthesized natriuretic peptide, which can be applied to preparation of medicaments for treating patients with acute heart failure, acute decompensated heart failure, acute myocardial infarction after coronary intervention, chronic heart failure, and acute anterior wall myocardial infarction with systolic heart failure of old people.

The invention relates to a prediction method and system for the survival rate of an acute myocardial infarction patient within 5 years. The method comprises the steps: acquiring clinical data of the acute myocardial infarction patient during hospital admission; establishing a prediction model according to the clinical data, establishing a column diagram of the survival rate within 5 years, calculating a total risk score, and then calculating a prediction value of the survival rate of the patient within 5 years; and outputting a predicted value of the survival outcome occurrence probability ofthe patient within 5 years. External verification proves that the method is suitable for Chinese people, statistical analysis is carried out by combining various potential risk factors influencing poor prognosis such as hospitalization baseline vital signs of acute myocardial infarction patients, operations and drug intervention, laboratory examination and imaging examination, factors related to the survival rate within 5 years are screened out, a prediction system for the survival rate of the acute myocardial infarction patient within 5 years is established, and a risk quantitative value is provided for clinicians to predict the survival rate of the acute myocardial infarction patient within 5 years more comprehensively and accurately.

The invention provides an lncRNA marker and application thereof in acute myocardial infarction diagnosis. The LncRNA marker is LINC01104, and the expression quantity of the LINC01104 in an acute myocardial infarction patient is lower than that of a normal person. The invention further discloses a fluorescent quantitative PCR kit for detecting acute myocardial infarction. The kit contains a reagentfor measuring expression of the LINC01104. Compared with a traditional biomarker, the LINC01104 marker has better tissue specificity and good stability, and the sensitivity and specificity of acute myocardial infarction diagnosis can be greatly improved.

The invention provides application of MED6 genes serving as an acute myocardial infarction risk prediction marker. The MED6 genes or gene expression products are taken as a novel acute myocardial infarction risk prediction and diagnoses and treatment target. The MED6 genes and expression products thereof are used for preparing acute myocardial infarction risk prediction markers and diagnoses preparations and have important clinical application significance and development values.

The invention discloses a miRNA-208a amplification primer pair based on chain exchange amplification and a detection kit thereof. The amplification primer pair comprises a forward primer and a reverse primer; the forward primer is composed of a 5' end side balance sequence and a 3' end side amplification sequence, and the amplification sequence is homologous with the 5' end side sequence of miRNA-208a-3p; and the reverse primer is composed of a 5' end side amplification sequence and a 3' end side balance sequence, and the amplification sequence is complementary with the 3' end side sequence of the miRNA-208a-3p. After an isothermal amplification reaction of the miRNA-208a is completed, a running buffer solution is added, the mixture is uniformly mixed and dropwise added to a sample adding window of a test strip, and a fluorescence signal is detected after 2 minutes. The detection method provided by the invention can be completed within 1 hour. The miRNA-208a detection method is simple, convenient, rapid and safe to operate, and an early molecular diagnosis detection method can be provided for acute myocardial infarction.

The present disclosure provides methods and compositions for treating coronary tissue damaged as a result of a cardiac disorder such as ischemia, acute myocardial infarction, vulnerable plaques, or reperfusion injury. Specifically, the cardiac disorder is treated using a multivalent molecule that is specific for a marker located, in or near the damaged coronary tissue and a marker located on a target cell (e.g., a stem cell). The multivalent molecule may be administered by intravenous injection, intra-arterial catheter, intramyocardial injection, or implantable device (e.g, stent).

The method comprises: simultaneously capturing multi biologic markers on one antibody component stroma; making the mass spectrum analysis for the captured variant biologic markers. It can simultaneously capture multi biologic marker groups and can be used for detecting the biologic marker combination in the body fluid already getting away from human body; said biologic marker combination can be used for identifying the shedding body fluid from normal person or acute myocardial infarction patient.

The invention provides an acute myocardial infarction real-time early warning system based on a wearable device. The acute myocardial infarction real-time early warning system comprises the wearable device, a mobile terminal and a cloud data processing module which is in communication connection with the wearable device and the mobile terminal; the wearable device is used for monitoring blood pressure, body temperature, respiratory rate, heart rate and electroencephalogram; the cloud data processing module is used for calculating a physiological parameter score and a consciousness state score in real time, calculating a real-time dynamic acute myocardial infarction score and determining an acute myocardial infarction danger level; the mobile terminal is used for displaying the acute myocardial infarction danger level in real time and selecting an early warning mode for early warning. According to the acute myocardial infarction real-time early warning system based on the wearable device, real-time dynamic early warning is provided for high-risk groups with acute myocardial infarction, the situation that a patient cannot see a doctor in time in an emergency of an acute cardiac event is prevented, and the case fatality rate of acute myocardial infarction is reduced.

The invention belongs to manufacture method and use method of rat tracheal intubation equipment, and particularly relates to a manufacture method and use method of tracheal intubation equipment of a rat acute myocardial infarction model. A needle core and an inner guide wire of the needle core are respectively a guide needle and a loach guide wire (Terumo super-slippery M-shaped loach guide wire in Japan) used for coronary artery intervention; the soft end of the guide wire penetrates through the tail end of the guide needle and is exposed from the head end of the guide needle by 0.4cm; and the redundant guide wire at the tail end of the guide needle is cut off. An outer-layer hose is prepared from an infusion needle of disposable venous infusion apparatus (Shanghai Youyu Medical EquipmentCo., Ltd., 0.5x20 infusion apparatus), wherein the length of the outer-layer hose is shorter than the length of a catheter needle by 0.3 cm, and the root of the hose is cut obliquely by a movable flap which accounting for 1 / 3 of the circumference of the hose. After anaesthesia, a rat is fixed and is subjected to skin preparation, a rat tongue is clamped out with a small tweezer, the tongue tip ispulled by a left hand, and a tracheal intubation pipe is hold by a right hand. A hard catheter needle at the head end of the tracheal intubation needle core is arranged at the root part of the rat tongue, and a trachea opening of the rat is searched by fine adjustment of the self-made tracheal intubation pipe under direct vision. The guide wire at the head end of the tracheal intubation pipe is sent in instantly when the trachea opening is opened, then the guide wire at the head end is inserted into the trachea opening by about 1cm through rotation, and the catheter needle is pulled out, wherein if the rat can breathe uniformly and smoothly, intubation is successful.

In the field of biological medicines, a use of prourokinase (proUK) and variants thereof in facilitated percutaneous coronary intervention (PCI) in patients with acute myocardial infarction is provided. The use includes: within 6 hrs after a patient is afflicted with accurate myocardial infarction (AMI), firstly, performing thrombolytic therapy with proUK or variants thereof, and then, performing a PCI operation, to dredge the infarction related artery (IRA) as soon as possible, and re-establish an effective forward blood flow, such that an ischemic myocardium is reperfused. According to the present invention, the facilitated PCI for treatment of AMI with the proUK or variants thereof has an effect superior to that of direct PCI.

The invention discloses a fusion protein of MNK2 protein kinase and a cell-penetrating peptide, a hydrogel of the fusion protein, and an application of the fusion protein in promoting myocardial regeneration, and belongs to the technical field of biomedicine. The fusion protein includes an MNK2 protein kinase sequence and a cell-penetrating peptide sequence, after injection, the fusion protein canaffect the process of cardiomyocyte cell cycle, mitosis and DNA synthesis by activating key pathways of the myocardial regeneration, reduce myocardial infarction area and fibrosis, promote myocardialregeneration repair after acute myocardial infarction, and improve recovery of a cardiac function; at the same time, a three-dimensional network structure formed by liquid coagulation of the small-molecular hydrogel can provide mechanical support force for a ventricle and delay ventricular remodeling; and the porous structure of the small-molecular hydrogel facilitates growth of regenerated cardiomyocytes, thereby promoting myocardial repair.

The invention discloses a gene for screening acute myocardial infarction complicated by cardiac rupture and an expression product thereof, which are characterized by application of the platelet factor4(PF4) gene and the expression product thereof to the preparation of an acute myocardial infarction risk prediction marker and a diagnostic preparation. The acute myocardial infarction risk prediction marker and the diagnostic preparation adopt conventional PCR (Polymerase Chain Reaction) relative quantification, a fluorescent quantification kit, protein hybridization, an enzyme-linked immunoassay method and a gene chip to assay the expression level of gene in the peripheral blood of a subject or a patient with acute myocardial infarction. The invention provides the application of the PF4 gene and / or the expression product of the gene as a novel marker for screening acute myocardial infarction complicated by cardiac rupture, provides a novel method for predicting and diagnosing the risk of acute myocardial infarction complicated by cardiac rupture by means of the PF4 gene or the expression product of the gene and utilizes the PF4 gene and the expression product thereof to prepare themarker for predicting the risk of acute myocardial infarction complicated by cardiac rupture and the diagnostic preparation for the first time.

The invention provides application of CD177 as a biomarker for detecting acute myocardial infarction, and relates to the technical field of biomedicine. The application can be used for predicting the attack of the acute myocardial infarction before the attack of the acute myocardial infarction to achieve the purpose of nipping in the bud, so that medical staff can better implement medical measures, the probability of sudden death of a patient due to the acute myocardial infarction is reduced The biomarker for detecting the acute myocardial infarction comprises CD177 protein and CD177 positive neutrophils, and the expression condition of the CD177 in a human body is used as a basis for judging the acute myocardial infarction. Compared with the original methods for detecting cardiac troponin T (cTnI), creatine kinase-MB (CK-MB) and the like as pathogenesis indexes of the acute myocardial infarction, the application has the advantages that the pathogenesis of the acute myocardial infarction can be predicted in advance, and a research direction is provided for predicting the pathogenesis time of the acute myocardial infarction in the future.

The present invention discloses a myocardial infarction treating cell preparation, a preparation method and applications thereof, wherein the main components in the cell preparation are CTs and BMSCs. According to the present invention, with the direct intracardiac injection or the interventional intracardiac injection of the cell preparation, by performing cell preparation transplantation on the ischemic area and ischemic margin area of the heart of acute myocardial infarction, the severely damaged cell network formed from CTs in the ischemic myocardium ischemic area can be effectively repaired and regenerated so as to repair the cell structure microenvironment beneficial for the regeneration of the infarcted myocardium, such that the regeneration of the infarcted myocardium is easily achieved; and after the transplantation treatment on the acute myocardial infarction, the effects in the fields of infarction area reducing, myocardial infarction heart cardiac function improving, ischemic myocardium fibrosis improving, ischemic area angiogenesis and marginal area angiogenesis promotion, infarcted heart pathological reconstruction improving and after-myocardial-infarction heart failure incidence reducing are superior to the effect of the current commonly-used separate BMSCs treatment.